The result indicated that MSI status can serve as a predictive biomarker for PD-1/PD-L1 checkpoint blockade therapy in CCA, but the incidence of MSI-H in CCA is low (1.3%, 4/308) according to the results of other study (24). This evidence concerns the gene CD274 and cholangiocarcinoma.